JP2018523665A5 - - Google Patents

Info

Publication number

JP2018523665A5

JP2018523665A5 JP2018506115A JP2018506115A JP2018523665A5 JP 2018523665 A5 JP2018523665 A5 JP 2018523665A5 JP 2018506115 A JP2018506115 A JP 2018506115A JP 2018506115 A JP2018506115 A JP 2018506115A JP 2018523665 A5 JP2018523665 A5 JP 2018523665A5

Authority

JP

Japan

Prior art keywords

pharmaceutically acceptable

enantiomer

solvate

acceptable salt

alkyl

Prior art date

2016-08-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 110
• 239000000203 mixture Substances 0.000 claims description 72
• 150000003839 salts Chemical class 0.000 claims description 71
• 239000012453 solvate Substances 0.000 claims description 71
• 125000000217 alkyl group Chemical group 0.000 claims description 42
• 125000003118 aryl group Chemical group 0.000 claims description 40
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 34
• 208000036142 Viral infection Diseases 0.000 claims description 32
• 229910052736 halogen Inorganic materials 0.000 claims description 32
• 125000001072 heteroaryl group Chemical group 0.000 claims description 32
• 230000009385 viral infection Effects 0.000 claims description 32
• 150000002367 halogens Chemical group 0.000 claims description 30
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
• 201000010099 disease Diseases 0.000 claims description 25
• 125000000623 heterocyclic group Chemical group 0.000 claims description 24
• 125000000304 alkynyl group Chemical group 0.000 claims description 22
• 229910052739 hydrogen Inorganic materials 0.000 claims description 18
• 125000003342 alkenyl group Chemical group 0.000 claims description 16
• 239000001257 hydrogen Substances 0.000 claims description 16
• 125000004429 atom Chemical group 0.000 claims description 14
• 208000035475 disorder Diseases 0.000 claims description 13
• 125000003545 alkoxy group Chemical group 0.000 claims description 12
• 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 10
• 150000002431 hydrogen Chemical group 0.000 claims description 10
• 125000004414 alkyl thio group Chemical group 0.000 claims description 9
• 239000008194 pharmaceutical composition Substances 0.000 claims description 9
• 208000006339 Caliciviridae Infections Diseases 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 7
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
• 125000005110 aryl thio group Chemical group 0.000 claims description 4
• 125000004104 aryloxy group Chemical group 0.000 claims description 4
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
• -1 —C 1 -C 6 alkylthio Chemical group 0.000 claims description 3
• 125000000539 amino acid group Chemical group 0.000 claims description 2
• 150000001413 amino acids Chemical class 0.000 claims description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
• 150000001768 cations Chemical class 0.000 claims description 2
• 125000005843 halogen group Chemical group 0.000 claims description 2
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
• 125000004043 oxo group Chemical group O=* 0.000 claims description 2
• 229910052760 oxygen Inorganic materials 0.000 claims description 2
• 0 CCC(C)[C@@](C(OC[C@]([C@@]([C@]1O)O)O[C@]1[n]1c2nc(C)nc(N)c2c(C(*)=O)c1)=O)N Chemical compound CCC(C)[C@@](C(OC[C@]([C@@]([C@]1O)O)O[C@]1[n]1c2nc(C)nc(N)c2c(C(*)=O)c1)=O)N 0.000 description 5
• 238000000034 method Methods 0.000 description 5
• 241001263478 Norovirus Species 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• VYNNKXUELOYRLV-WLDCSJRQSA-N CC(C)C[C@@H](C(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2nc(C)nc(N)c2c(C(N)=O)c1)=O)NC(OCC1c2ccccc2-c2c1cccc2)=O Chemical compound CC(C)C[C@@H](C(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2nc(C)nc(N)c2c(C(N)=O)c1)=O)NC(OCC1c2ccccc2-c2c1cccc2)=O VYNNKXUELOYRLV-WLDCSJRQSA-N 0.000 description 1
• BAPFUTVTYJTUAK-DSFOBNFRSA-N C[C@@H](C(OCc1ccccc1)=O)NP(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](cc1C(N)=O)c2c1c(N)nc(C)n2)(Oc1ccccc1)=O Chemical compound C[C@@H](C(OCc1ccccc1)=O)NP(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](cc1C(N)=O)c2c1c(N)nc(C)n2)(Oc1ccccc1)=O BAPFUTVTYJTUAK-DSFOBNFRSA-N 0.000 description 1
• WLCTVUNWTINQMW-HTVVRFAVSA-N Cc1nc([n]([C@@H]([C@@H]2O)O[C@H](COP(O)(O)=O)[C@H]2O)cc2C(N)=O)c2c(N)n1 Chemical compound Cc1nc([n]([C@@H]([C@@H]2O)O[C@H](COP(O)(O)=O)[C@H]2O)cc2C(N)=O)c2c(N)n1 WLCTVUNWTINQMW-HTVVRFAVSA-N 0.000 description 1